• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

What Is Behind the Current Chip Correction Move?

Dutch-rooted lithographic equipment maker ASML has kicked off a corrective wave of decline in European and Asian markets on July 17, which quickly echoed in the chip segment on Wall Street as well. The EU technology sub-index dropped by 4.5% marking the most substantial one-time fall for the last 18 months and the U.S. tech-heavy Nasdaq Composite index plummeted by 2.75% to challenge the area below 18,000 technical support, which was an all-time resistance level before July. American Depositary Receipts (ADRs) of ASML suddenly shed almost 12% of its market value, sparking concerns of a massive rotation away from tech stocks to industrials and smaller caps.

It was amazing that the Dow Jones index (DJIA) closed above 41,000 for the first time ever (228 points, or 0.6%, of daily rise) at the very moment when the broader S&P 500 and its AI-related flagships including NVIDIA lost their upside steam. This fact emphasizes the reallocation of money, and not the outflow from equities to the cash, as it happens in times of crisis or stock crashes. Nominally, ASML posted quite decent second quarter figures on both equity per share (EPS) of $4.01 ($0.02 better than consensus forecast) and somewhat lower revenue of $6.24 billion vs the average expectations of $6.49 billion. Yet, the weak point by this giant chip-making equipment manufacturer was its disappointing forward guidance, with supposed Q3 sales between $6.70 billion and $7.30 billion, compared to higher Wall Street expert pool estimates of $8.32 billion. At the same time, ASML's stock price was clearly overheated after rallying nearly 25% during the recent three months, and now it only returned to its levels of late May. Thus, downstairs sliding is fast, but it's not a disaster yet.

A double-digit drop in ASML shares could go rather smoothly for other AI leaders, if not the synchronous news came from U.S. government sources, as whistleblowers said regulators might consider more severe trade restrictions in order to suppress China's access to advanced chip know-hows. If firms such as ASML, NVIDIA and AMD continue to send advanced semiconductor decisions to Asian markets, the White House subordinates may impose a measure called FDPR (the foreign direct product rule) to control on foreign-made products, which use even the tiniest amount of U.S.-licensed technology.

This kind of threat could be how the U.S. wants to push European and Japanese companies to restrict their contacts with Chinese firms, and the spectre of a trade war is here again, inside investing minds. Again, the sectoral leaders like NVIDIA and AMD have already learned to bypass most of the former restrictions. However, in combination with moderate demand concerns and covering a big distance in a short time by hyping AI stocks, this prompted an immediate profit taking, so that NVIDIA and Micron (MU) lost nearly 6.5%, Broadcom (AVGO) dropped by 8%, while AMD corrected by more than 10% in one trading session.

Further price developments in the nearest couple of days will show how deep the correction may go, but the major fundamental conception suggests that too rapid decline is typically temporary and short-lived on such an advanced stage of the lasting uptrend, as it has the solid AI-related nature.

3283
B
J&J Has More on the Upside

Johnson & Johnson's earnings beat consensus quarterly estimates by $0.10 per share, compared to Wall Street pool average forecast of $2.72. A hygienic product giant reported its Q2 sales at $22.45 billion, so that the number came out barely above analyst expectations of $22.34 billion, yet marking a nearly $1 billion (+5%) surplus vs the median sales for the previous three quarters. Actually, a great one-time improvement after many months of stagnation, even though fixing a 12% fall YoY in terms of revenue. From my point of view, the J&J business became more effective, as it provided almost the same income on a lower gross money basis, which means the ability to generate higher marginality. The latest report did not provide an immediate upside momentum for the stock. J&J share price even lost a few tenths of a percent in the pre-market trading today. Yet, the first market's response did not defy the recent technical bounce when J&J drifted off the $145 support area.

The price is still trying to consolidate above $150, which means growing confidence in the company's recovery so that the investing crowd presumably keeps in mind at least a $160 to $165 range as the short-term target area. If only the stock would close today above $150, I would be ready to buy and hold it. I personally feel the fundamental environment is now healthier. The company's management does not say the mountains are trembling, but instead it sees financial 2024 earnings at $10.05 per share vs the analyst average forecast of $10.01, according to Refinitive. It now expects total 2024 sales of $89.2 billion to $89.6 billion, vs prior forecast of $88.7 billion to $89.1 billion. Only the segment of medical technology business by J&J rose 2.2% to $7.96 billion from $7.79 billion ⁠YoY, which was less than consensus bets of $8.17 billion. With a trend of re-directing some part of money flows from high-flying AI-related megacaps led by NVIDIA to midcaps, such a small but positive revision may be enough to attract more investors' attention. J&J also announced a cash dividend of $1.24 per share on the company's common stock, payable on September 10, the ex-dividend date is August 27.

If one exclude a contribution of the COVID-19 vaccine, which is out of time, J&J's operational sales even grew by 7%, which may be attributed to the advancement of its product pipeline, including TREMFYA (to treat adults with psoriasis), RYBREVANT (a first-line treatment for non-small cell lung cancer), and the VARIPULSE platform (showing at least 12-month freedom from atrial arrhythmia recurrence in approximately 80% of the patients). The system, integrating a multi electrode catheter, a multi-channel pulsed field ablation generator and a cardiac mapping system, has been approved in January in Japan and partially in Europe, still waiting an approval by the US Food and Drug Administration (FDA), remaining as currently investigational for North America patients. J&J has more space upside in this regard, meaning better prospects in innovative oncology and immunology.

Of course, robust sales of its major drugs like blood cancer therapy Darzalex and psoriasis drug Stelara are always here. Stelara sales added 3.1% to $2.89 billion YoY, while Darzalex sales jumped as much as 18.4% to $2.88 billion. Stelara sales of more than $10 billion are expected in 2024, yet some analysts expect the figure may fall to $7 billion in 2025, as several close copy drugs are going to be launched by J&J rivals. To smooth the effect, the company is finalizing deals to make favourable U.S. insurance coverage for Stelara soon. A cancer cell therapy, named Carvykti, got sales of $186 million, up 60% YoY, even being watched below the $200 million analyst consensus prediction, limited only by tight supply, according to J&J. If so, I don't see large weaknesses in the company's drug line-up.

4533
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
REN is Challenging its Downtrend

Ren (REN) is adding 10.7% to $0.0505 this week, slightly retreating from its $0.0513 peak on Tuesday. Most importantly, the token has returned to the support at $0.0500. It is now attempting to hold above this level and possibly approach the resistance of the downtrend at $0.0595. If this level is surpassed, the token will target $0.0750. This optimistic scenario is supported by Bitcoin (BTC), which is targeting $70,000. A Bitcoin rally may help REN climb by another 16.0% to $0.0595. If BTC continues above its all-time high, REN is likely to continue rising, breaking through the downtrend resistance.

4672
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
ATOM is Keeping Its Upside Momentum

Cosmos (ATOM) is rising by 1.5% to $6.310 this week, though it was 5.0% higher at $6.605 on Tuesday. The token retreated after a cautious breakthrough of the downtrend resistance. This could be positive for the upside scenario if prices hold above $6.25. This may push prices further up towards $7.00, or by 18.5%.

Bitcoin (BTC) is also rising above the support at $60,000 with a perspective to climb to $70,000, which could support ATOM as well. Additionally, Cosmos network developers have announced that its decentralized VPN, which uses ATOM as a native token, is almost completed. This development is also positive for ATOM's prices.

3249
151

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors